Multicenter phase II study of combination chemotherapy with IRIS and Cetuximab as second line therapy in patient with colorectal cancer
Phase 2
Recruiting
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000006793
- Lead Sponsor
- ippon Medical School Musashikosugi Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) History of severe allergy 2) Simultaneous or metachronous double cancers 3) active infectious disease, 4) Severe comorbidity 5) Massive pleural effusion or ascites 6) Wattery diarrhea 7) Paralytic or mechanical bowel obstruction 8) Symptomatic brain metastasis 9) Patients who is receiving Fluorocytosine or Atazanavir Sulfate 10) Pregnant or lactating women or women of childbearing potential. 11) Amalgamation of mental disease or psychotic manifestation 12) Patients who are inadequate by investigator's decision.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method progression free survival overall survival disease control rate re-resection rate adverse event dose intensity